KOENIG DAVID 4
4 · ProUroCare Medical Inc. · Filed Jan 2, 2013
Insider Transaction Report
Form 4
KOENIG DAVID
Director
Transactions
- Award
Common stock, $0.00001 par value
2012-12-28$0.64/sh+7,552$4,833→ 195,876 total
Holdings
- 50,000
Stock options
Exercise: $1.50Exp: 2016-09-29→ Common stock, $0.00001 par value (50,000 underlying) - 26,571(indirect: Shares held by Clinical Network Inc., of which the reporting person is a managing officer.)
Common Stock, $0.00001 par value
- 25,000
Stock Options
Exercise: $0.60Exp: 2019-08-09→ Common stock, $0.00001 par value (25,000 underlying) Convertible Note
Exercise: $1.10Exp: 2012-12-28→ Common stock, $0.00001 par value- 1,875(indirect: Shares held by Clinical Network Management Corp., of which reporting person is a managing officer.)
Common Stock, $0.00001 par value
- 14,535
Stock Options
Exercise: $1.72Exp: 2017-08-10→ Common stock, $0.00001 par value (14,535 underlying) - 50,000
Warrants
Exercise: $1.30Exp: 2013-08-02→ Common stock, $0.00001 par value (50,000 underlying) - 28,736
Stock options
Exercise: $0.87Exp: 2018-08-09→ Common stock, $0.00001 par value (28,736 underlying)
Footnotes (4)
- [F1]Currently exercisable.
- [F2]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors. The seven-year options vest ratably over 12 months.
- [F3]On December 1, 2011, the reporting person and the Company executed a convertible promissory note in the principal amount of $6,400 with a maturity date of February 28, 2012. The maturity date was subsequently changed to December 28, 2012. The principal amount and interest accruing at a rate of 10% per year are convertible into common shares at $1.10 per share until such time as the note is re-paid. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).
- [F4]Shares issued to directors in payment of directors' fees earned during the period from July 1, 2012 and December 31, 2012, in lieu of cash. The Issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rule 16b-3(d).